Can Fite BioPharma Ltd (CANF)

[midastouch017]

Can-Fite cannabis compound inhibits liver cancer growth

Apr. 05, 2021 7:43 AM ETCan-Fite BioPharma Ltd. (CANF)
By: Mamta Mayani, SA News Editor

Can-Fite BioPharma (NYSEMKT:CANF) has completed pre-clinical studies demonstrating that a CBD rich T3/C15 cannabis fraction induces inhibition of liver cancer cell growth.

T3/C15 cannabis fraction inhibited the growth of liver HEP-3b hepatocellular carcinoma cells via the A3 adenosine receptor (A3AR) by inhibiting Wnt- and NF-kappa B-related regulatory pathways, known to be highly active in controlling the growth of liver cancer cells.

An A3AR antagonist, MRS1523 reversed this effect demonstrating that the inhibitory effect is mediated via Can-Fite’s target, A3AR.

Can-Fite drug candidate Namodenoson is expected to enter a Phase III study in Q4 2021.

The Company has filed patent applications protecting its discovery of cannabinoid-based therapies where the A3AR target is overexpressed including liver cancer.

According to Adroit Market Research, the medical cannabis market is projected to grow at a CAGR of 29% to $56.7B by 2026. DelveInsight estimates the HCC drug market will reach $3.8 B in 2027 in the G8 countries.